{"DataElement":{"publicId":"6755040","version":"1","preferredName":"Entrectinib Special Event of Interest Document Occurrence Descriptive Text","preferredDefinition":"The text that provides a description of the patients entrectinib special event of interest occurrence.","longName":"6753958v1.0:2181231v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6753958","version":"1","preferredName":"Entrectinib Special Event of Interest Document Occurrence","preferredDefinition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types._Records of an event experienced by a subject in a clinical trial, which is defined by the clinical study protocol as significant._An instance of something happening, such as an event or incident.","longName":"6753954v1.0:6753956v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6753954","version":"1","preferredName":"Entrectinib","preferredDefinition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","longName":"C114984","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entrectinib","conceptCode":"C114984","definition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8877E805-32C5-6E6F-E053-F662850A0214","latestVersionIndicator":"Yes","beginDate":"2019-05-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-05-09","modifiedBy":"ONEDATA","dateModified":"2019-05-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6753956","version":"1","preferredName":"Special Event of Interest Document Occurrence","preferredDefinition":"Records of an event experienced by a subject in a clinical trial, which is defined by the clinical study protocol as significant.:An instance of something happening, such as an event or incident.","longName":"C115558:C25275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Special Event of Interest Document","conceptCode":"C115558","definition":"Records of an event experienced by a subject in a clinical trial, which is defined by the clinical study protocol as significant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8877E805-32D7-6E6F-E053-F662850A0214","latestVersionIndicator":"Yes","beginDate":"2019-05-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-05-09","modifiedBy":"ONEDATA","dateModified":"2019-05-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8877E805-32E8-6E6F-E053-F662850A0214","latestVersionIndicator":"Yes","beginDate":"2019-05-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-05-09","modifiedBy":"MORENOC","dateModified":"2019-11-06","changeDescription":"11/6/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181231","version":"1","preferredName":"Descriptive Text","preferredDefinition":"The text that provides a description of a topic.","longName":"DESCR_TXT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B72801-8C4C-3772-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2004-02-19","modifiedBy":"GDEEN","dateModified":"2022-05-31","changeDescription":"3/22/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Brief description of special","type":"Preferred Question Text","description":"Brief description of special situation:","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"88858D81-E1B8-4799-E053-F662850AB53A","latestVersionIndicator":"Yes","beginDate":"2019-05-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-05-10","modifiedBy":"MORENOC","dateModified":"2020-01-08","changeDescription":"1/8/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}